Literature DB >> 1761797

Immunotoxicity of tri-n-butyltin oxide (TBTO) and tri-n-butyltin chloride (TBTC) in the rat.

G Bressa1, R H Hinton, S C Price, M Isbir, R S Ahmed, P Grasso.   

Abstract

In a 1-month feeding trial, pure and commercial tri-n-butyltin oxide (TBTO) and tri-n-butyltin chloride (TBTC) were fed to rats at concentrations of 5 ppm and 25 ppm. At all times, the mean body weight gain and the food consumption was significantly less in rats treated with 25 ppm pure TBTO or pure TBTC as compared to control rats or rats receiving commercial TBTO. Histological examination of the thymus of rats treated for 7 days with TBTO showed atrophy with severe lymphocytic depletion in the cortex. After 28 days of exposure, most of the lesions reversed and the thymus became markedly smaller than in control rats, both in absolute terms and in relation to body weight. Seven days of exposure to TBTO increased liver weight but this change was reversed during a further 3-week exposure. Tin concentrations were the highest in livers and kidneys. Concentrations in the thymus were less than one-fifth of hepatic values. Changes in the rats treated with the commercial TBTO were very similar. Rats treated with TBTC showed lower tin levels and less immunotoxicity as compared to those treated with TBTO.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1761797     DOI: 10.1002/jat.2550110604

Source DB:  PubMed          Journal:  J Appl Toxicol        ISSN: 0260-437X            Impact factor:   3.446


  2 in total

1.  From the Cover: Tributyltin Alters the Bone Marrow Microenvironment and Suppresses B Cell Development.

Authors:  Amelia H Baker; Ting Hua Wu; Alicia M Bolt; Louis C Gerstenfeld; Koren K Mann; Jennifer J Schlezinger
Journal:  Toxicol Sci       Date:  2017-07-01       Impact factor: 4.849

2.  Tributyltin protects against ovariectomy-induced trabecular bone loss in C57BL/6J mice with an attenuated effect in high fat fed mice.

Authors:  Rachel Freid; Amira I Hussein; Jennifer J Schlezinger
Journal:  Toxicol Appl Pharmacol       Date:  2021-10-05       Impact factor: 4.219

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.